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Abstract
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disease that
results in gradual cognitive impairment and eventually leads to dementia. However,
despite AD being one of the most prevalent neurodegenerative diseases in aging societies,
no clinically successful therapeutic strategies for its treatment or prevention have been
reported to date. Studies have indicated that gut microbial alterations are linked to AD.
Probiotics are living microorganisms that are known to confer health benefits to the host
when ingested in adequate amounts. Certain strains of probiotics appear to influence the
central nervous system (CNS) and behavior via the microbiota-gut-brain axis. Increasing
evidence from preclinical and clinical studies has demonstrated that probiotics possess
preventive as well as therapeutic potential for AD. It is speculated that probiotics could
ameliorate the progression of AD by modulating the inflammatory process, counteracting
oxidative stress, and other possible mechanisms, although further studies are needed to
understand the details. In this chapter, we will highlight the current understandings of the
effects as well as the possible mechanisms of action of probiotics for preventing cognitive
impairment in AD.
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1. Introduction
Alzheimer’s disease (AD) is the most common form of neurodegenerative disease and the
leading cause of dementia in the elderly, accounting for an estimated 60–80% of dementia
cases worldwide [1]. It is a highly incapacitating disorder, progressing from gradual deterio-
ration of memory and cognitive functions to a complete incapacity, which consequently leads
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to death of patients within 3–9 years after diagnosis [2]. Aging is recognized as the major risk
factor of all AD cases, and the aging of world population will lead to a steep increase in the
prevalence of AD [1]. Despite much effort has been made in AD research in the past few
decades, the pathophysiology of AD remains unclear, and to date, there is no effective thera-
peutic treatment for the disease. Hence, new therapeutic solutions that can effectively combat
the disease are of utmost importance.
Recent studies have shown that the gut microbiota is involved in the neurodegenerative
disorders and diverse cognitive functions through regulating the gut-brain axis [3, 4]. The
concept of microbiota-gut-brain axis is emerging and its dysregulation has now been linked
to the progression of AD [5]. In light of this, it is suggested that modulation of the gut
microbiota through the use of probiotics might possibly prevent or ameliorate AD symptoms.
In this chapter, we discuss the roles of the gut microbiota in the development of AD, highlight-
ing the specific contribution of probiotics intervention to the amelioration of AD progression.
We examine recent scientific literature addressing the beneficial effects of probiotics for the
prevention and treatment of AD and point out the possible mechanisms of action of probiotics
for preventing cognitive impairments in AD.
2. Clinical features and pathogenesis of Alzheimer’s disease
AD is a chronic progressive neurodegenerative disorder characterized by three clinical phases
in which the patients exhibit different symptoms over time [6]. The first stage (early stage; mild
AD) includes memory loss, language difficulties, and executive dysfunction. The second stage
(middle stage; moderate AD) comprises psychiatric symptoms and behavioral disturbances
such as depression, hallucinations, delusions, and agitation. The third stage (late stage; severe
AD) comprises severe impairment of almost all cognitive functions and difficulties to perform
activities of daily living. The symptoms of AD worsen gradually, and the disease may begin to
develop decades before the manifestation of the earliest clinical symptoms [7].
Despite the massive worldwide research efforts that have been made in the past few decades,
the exact cause and pathogenesis of AD are not fully understood. It is widely believed that the
pathogenesis of AD is primarily driven by the abnormal deposition of extracellular β-amyloid
peptide (Aβ) plaques in various areas of brain, although such hypothesis may not be the sole
explanation [8, 9]. Aβ is a peptide consists of 37–43 amino acids, in which Aβ42 is a more
prevalent isoform and is considered to be the most neurotoxic in nature [10]. Aβ is derived
from the sequential proteolytic enzymatic cleavage of amyloid precursor protein (APP) by two
membrane-bound proteases, β- and γ-secretase [11, 12]. In the amyloid cascade hypothesis of
AD, the disease is characterized as a series of abnormalities in the process and secretion of the
amyloid precursor protein (APP), where an imbalance between production and clearance of
Aβ is the triggering event that leads to the accumulation of Aβ in the brain parenchyma [13].
As a consequence, Aβ spontaneously aggregates into soluble oligomers that are eventually
deposited in diffuse senile plaques [14]. The Aβ deposition and diffused senile plaques
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formation eventually lead to local microglia activation and production of pro-inflammatory
cytokines [15, 16]. In turn, these cytokines stimulate reactive astrocytes to produce further
amounts of Aβ42 oligomers, thus activating more amyloid plaque formation [17]. In addition,
Aβ oligomer aggregations induce oxidative damage, which, in turn, seem to provoke inflam-
mation and facilitate tau hyperphosphorylation, resulting in adverse effects on neuronal syn-
apses and mitochondria [18].
Neurofibrillary tangles (NFTs), which are filamentous inclusions that accumulate in selective
neurons of AD brains, are another major pathological hallmark of AD. The major component
of NFTs is the microtubule-associated protein tau [19, 20]. The tau protein is a highly soluble
protein that promotes microtubule assembly and stabilization for axonal transport and neuro-
nal growth under normal conditions [21]. In AD, the tau protein exhibits altered solubility
properties, becomes abnormally hyperphosphorylated, and forms filamentous structures [22].
Hyperphosphorylation of tau is known to induce a lower grade of interaction of tau proteins
with microtubules that leads to greater self-aggregation of tau proteins and consequently
induces malfunction of axonal transport [23], mis-stabilization of actin [24], synaptic impair-
ment [25], and defects in mitochondrial integrity [26].
Nevertheless, NFTs seem not to be the main toxic entities leading to AD. Recent studies show
that the intermediate tau oligomer is likely to be the key attribute of disease onset [27, 28].
Appearing prior to NFTs formation, hyperphosphorylated tau self-assembles into oligomeric
forms and insoluble materials as paired-helical filaments (PHFs), triggering neurotoxic actions
that affect the normal interaction patterns of the neuronal cytoskeleton and neuronal damage
[28, 29]. As a result of neuronal death, tau oligomers are released into the extracellular envi-
ronment, contributing to microglia activation with overproduction of pro-inflammatory cyto-
kines that trigger deleterious signal cascades leading to progressive neuronal degeneration in
AD brains [30]. Although the exact cause on why AD onset takes decades before symptoms
occur remains unclear, AD progression is likely related to a reduced ability to eliminate
misfolded, oligomerized, and aggregated tau proteins that increase with advancing age.
Therefore, tau protein could be another important therapeutic target in AD pathology.
3. Gut microbiota and Alzheimer’s disease
3.1. Microbiota-gut-brain axis
The gut-brain axis has long been recognized as a bidirectional communication between the
brain and the gut in which the brain communicates with the gastrointestinal tract by modulat-
ing permeability, motility, secretion, and immunity, and concurrently, the gut can affect brain
function and behavior [31]. The complex and multifaceted network of gut-brain axis consists of
the gastrointestinal tract, central nervous system (CNS), autonomic nervous system (ANS),
enteric nervous system (ENS), neuroendocrine system, and immune system which drive vari-
ous afferent and efferent pathways such as vagus nerve and hypothalamic-pituitary adrenal
(HPA) pathway for regulation of immune and metabolic homeostasis [31]. Recently, it is
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becoming increasingly evident that gut microbiota play a pivotal role in regulating the gut-
brain axis, thereafter the term microbiota-gut-brain axis was introduced [32–34].
Gut microbiota is proposed as a key regulator of centrally mediated events including meta-
bolic homeostasis, immune function, and neurological diseases [33]. Gut microbiota is a com-
plex community composed of trillions of microorganisms, mainly bacteria, but also
bacteriophage particles, viruses, fungi, and archaea [35]. A majority of the microbiota belongs
to the two bacterial phyla, Bacteroidetes and Firmicutes, while Proteobacteria, Actinobacteria,
Fusobacteria, and Verrucomicrobia phyla are present in lower proportions [36]. Notably, it is
increasingly evident that alterations in the gut microbiota composition may cause imbalanced
gut homeostasis and detrimental effects on CNS [37]. For instance, a variety of gastrointestinal
and metabolic diseases including inflammatory bowel disease (IBD), obesity, diabetes, and
insulin resistance are common comorbidities in many neurological disorders [38]. More
recently, metagenomics studies have revealed that gut dysbiosis is present in a variety of
neurological diseases including AD. Consequently, it is inevitably important to maintain a
well-balanced and healthy microbiota community in the regulation of gut-brain axis.
3.2. Gut microbiota alterations and Alzheimer’s disease
Accumulating evidence suggests that gut microbiota alterations can influence the progression
of neurological disease and may be a major factor in the development of AD [39, 40]. For
instance, a recent preclinical study revealed a remarkable shift in the gut microbiota of APP
transgenic mice as compared to healthy, wild-type mice, wherein a significant reduction in
bacteria belonging to the phyla Firmicutes, Verrucomicrobia, Proteobacteria, and Actinobacteria
with respect to an increase of Bacteroidetes and Tenericutes was observed in the intestine of
conventionally raised transgenic APPPS1 AD mice [41]. It was strongly advocated that a
distinct microbial constitution in AD mice may contribute to amyloid deposition wherein a
remarkable increase in cerebral Aβ pathology was observed in APP transgenic germ-free mice
colonized with microbiota from conventional APP transgenic mice, while control mice colo-
nized with microbiota from wild-type mice was less effective in increasing cerebral Aβ levels
[41]. In addition, a clinical study characterizing the gut microbiota composition of AD subjects
reveals decreased microbial diversity and changes in bacterial abundance compared with
controls; these changes include decreased levels of Firmicutes and Bifidobacterium and
increased levels of Bacteroidetes [42]. Nonetheless, the exact causes and effects of gut dysbiosis
on AD remain elusive.
It is plausible that microbiota alterations can lead to colonization of intrinsic pathogens and
increase gut permeability that could perturb the gut-brain axis. For instance, recent study has
demonstrated that enterobacteria infection exacerbated progression of AD by promoting
immune hemocyte recruitment to the brain; thereby provoking tumor necrosis factor-c-Jun
NH2-terminal kinase (TNF-JNK)-mediated neurodegeneration in a drosophila AD model [43].
Additionally, the intestinal opportunistic bacteria including Bacillus subtilis, Escherichia coli, Kleb-
siella pneumonia,Mycobacterium spp., Salmonella spp., Staphylococcus aureus, and Streptococcus spp.
have been found to excrete immunogenic compounds of amyloids, lipopolysaccharides (LPS),
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and other microbial exudates into their circumjacent environment [44]. For instance, LPS and
the E. coli K99 pili protein were highly detected in the brain parenchyma and blood vessels of
AD patients [45]. Additionally, LPS was found to colocalize with Aβ in amyloid plaques,
suggesting that bacterial components can translocate from the gut, assessing the brain and
further triggering Aβ deposition in AD [45]. It has also been hypothesized that bacterial-
derived amyloids may reach the systemic circulation and accumulate in the brain, thereby
triggering a series of downstream events that leads to impairment of phagocytosis and con-
tributes to Aβ42 deposition, resulting in dysfunction of specific brain regions, such as the
cerebellum and the hippocampus [46, 47].
Another clinical study involving 83 elderly subjects (40 cognitive-impaired amyloid-positive
patients, 33 cognitive-impaired amyloid-negative patients, and 10 cognitively healthy amyloid-
negative controls) have demonstrated that an increased abundance of a pro-inflammatory gut
microbiota taxon, Escherichia/Shigella, and a reduced abundance of an anti-inflammatory taxon,
Enterococcus rectale, are possibly associated with a peripheral inflammatory state in patients with
cognitive impairment and brain amyloidosis [48]. The results obtained from the study indicated
the role of amyloid and related bacterial accumulation in the pathogenesis of cognitive damage
[48]. A remarkable recent study using APP transgenic mice model has also demonstrated that
AD pathology shifted gut microbiota composition during aging toward an inflammation-related
bacterial profile and suggested that these changes could contribute to disease progression and
severity [49]. Taken together, these findings highlight an intricate association between gut
microbiota alterations and amyloid formation, increased systemic inflammatory responses and
cognitive impairment in AD, suggesting modulation of gut microbiota with probiotics could be a
promising therapy to alleviate its underlying symptoms.
4. Probiotics modulation of Alzheimer’s disease
The connections between gut microbiota and AD have led to a great interest in modulation of
the microbiota-gut-brain axis through probiotics. Probiotics are defined as live microorgan-
isms that, when consumed in sufficient amounts, confer health benefits to the host [50]. The
probiotics species that are most commonly studied usually belong to the genera Lactobacillus or
Bifidobacterium, whereby some of the members are the natural inhabitants of the gut microbiota
and generally regarded as safe. In recent years, the possibilities of probiotics exerting a positive
cognitive effect in human health have emerged. A growing body of animal studies supports
the idea that certain probiotics can counteract gut dysbiosis and may positively impact the
pathogenesis of AD. Nonetheless, clinical data are less compelling than the animal model data.
4.1. Animal studies
Studies in rodents indicate that cognition and memory storage, particularly the hippocampal
long-term potentiation, begin to decline in aging animals and these brain functions are dra-
matically disrupted in animal models of AD [51]. Many lines of evidence have shown that
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probiotics modulation of the gut microbiota could improve age-related cognitive functions in
animal models. For instance, treatment with VSL#3, a probiotics mixture containing eight
different Gram-positive bacterial species, showed a significant alteration in gut microbiota,
with increases in Actinobacteria and Bacteroidetes, both of which were reduced in vehicle-
treated animals with a positive impact on long-term potentiation, inflammation, and neural
plasticity [52]. Moreover, it was demonstrated that long-term dietary supplementation of
multispecies live Lactobacillus and Bifidobacterium mixture (Lab4) to aging rats changes the
brain metabolites (γ-aminobutyric acid (GABA) and glutamate) that are involved in neural
signaling in the frontal cortex and hippocampus and improves task-specific memory [53].
Collectively, these findings represent proof of principle that probiotic modulation of gut
microbiota can have a positive impact on cognitive functions and suggest a possible role of
memory-enhancing probiotic strains in preventing cognitive impairment in AD.
A recent study has provided direct evidence for amelioration of cognitive dysfunction by
probiotics treatment with the strain of Bifidobacterium breve strain A1 using Aβ-induced AD
mice model (Figure 1). Administration of B. breve A1 to ADmice attenuated the impairment of
alternation behavior in a Y maze test and reversed the reduced latency time in a passive
avoidance test, indicating that B. breve A1 prevented cognitive dysfunction [54]. In addition to
the promising effect on cognitive function, B. breve A1 also suppressed the immune response
and neuronal inflammation induced by Aβ. Moreover, SLAB51 probiotic formulation, which
consists of a mixture of lactic acid bacteria and bifidobacteria, was shown to reduce brain
damage and Aβ aggregations and prevents the onset and delay progression of AD in mice in
the early stage of AD [55]. Another report using Aβ1-42-intra-hippocampal injected rats have
also demonstrated that the administration of probiotics, which consisted of L. acidophilus,
L. fermentum, B. lactis, and B. longum, could improve the common pathological features of AD
including spatial memory and learning deficits and oxidative stress [56]. Taken together, these
animal studies show that probiotics may play an important role in the bidirectional communi-
cation between the gut and the brain, and support the notion that probiotics modulation could
ameliorate the development of AD; however, it clearly requires translation in humans.
4.2. Human studies
The health benefits of probiotics on numerous aspects of host health and homeostasis have
been extensively studied in clinical trials. However, a detailed analysis of probiotics modula-
tion in patients with AD is lacking and the effects of probiotics on the onset, symptoms, and
pathogenesis of AD remain uncover. To date, there is only one clinical study of probiotics in
subjects with AD has been carried out. The randomized, double-blind, and controlled clinical
trial involved 60 patients with AD who were randomly assigned into two groups: the
probiotics group (n = 30), received 200 ml/day of milk enriched with L. acidophilus, L. casei,
B. bifidum, and L. fermentum (2  109 CFU/g each) for 12 weeks, and the control group (n = 30)
received plain milk at the same amount [57]. All participants were introduced to the mini-
mental state examination (MMSE) cognitive test for evaluation of learning and memory. After
12 weeks intervention, probiotic administration has significant improvement in the MMSE
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score of the subjects with AD in which the score (out of 30) was significantly increased in the
probiotic group (from 8.67  1.44 to 10.57  1.64, +27.90  8.07%) as compared to control
group (from 8.47  1.10 to 8.00  1.08, 5.03  3.00%). The probiotic treatment also has
favorable effects on the levels of malondialdehyde (MDA) and high-sensitivity C-reactive
protein (hs-CRP), improved insulin resistance, pancreatic beta cell secretion, and metabolic
status with respect to controls; albeit the changes in other biomarkers of oxidative stress and
inflammation, fasting plasma glucose (FPG) and other lipid profiles are negligible [57]. Based
on the MMSE scores, the patients included in this study were having severe AD. It is generally
recognized that the physiological effect of probiotics on human health is preventive but not
therapeutic, thus, it is surprised to find a prominent effect of this probiotics mixture on patients
with severe AD. Further investigations on the effects of probiotics on mild cognitive impair-
ment (MCI) and moderate AD are undoubtedly needed. Collectively, the results from both
animal and clinical studies offer hope for the future development of a novel probiotics-based
approach to ameliorate symptoms of AD and provide a useful framework to explore the
microbiota-brain axis.
Figure 1. Probiotics intervention could potentially modulate cognitive decline in Alzheimer’s disease (AD) via the
microbiota-gut-brain axis. A prominent strain of probiotic, Bifidobacterium breve A1 ameliorated cognitive impairment in
Aβ-induced AD mice model wherein administration of B. breve A1 to AD mice attenuated the impairment of alternation
behavior in a Y maze test and reversed the reduced latency time in a passive avoidance test.
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5. Possible mechanisms of action of probiotics in preventing Alzheimer’s
disease
5.1. Modulation of immune reactions
Although many lines of evidence have shown the potential effects of probiotics in treating AD,
the mechanisms of action are still speculated and unclear. One mechanism is the modulation of
immune reactions. Accumulating evidence suggests that neuroinflammation has a causal role
in the pathogenesis of AD wherein neuroinflammation is not a passive system activated by
senile plaques and NFTs, but instead contributes as much as the plaques and tangles in AD
[58]. This is substantiated by the presence of microglia cells in both AD patients and animal
models of AD [59], and it is accompanied by increased levels of pro-inflammatory cytokines,
such as TNF-α or interleukin (IL)-6 as found in the serum and brain tissue of AD patients [60].
In AD, aggregated Aβ as well as hyperphosphorylated tau proteins interfere with neuronal
function and trigger the inflammatory activity of microglia [61]. Microglia activation leads to
further accumulation of Aβ, neuronal debris, and, most probably, the sustained production of
pro-inflammatory cytokines and reactive oxygen species (ROS), giving rise to a chronic,
nonresolving inflammatory process [62]. Inevitably, modulation of neuroinflammation pro-
vides compelling targets for interventions in AD.
Probiotics intervention has been reported to improve the age-associated modifications of
immunological features. It was demonstrated that probiotic treatments can ameliorate the
immune reactions by modulating cytokine production, improving distribution and function
of natural killer cells, macrophages, granulocytes, and T cells, and enhancing mucosal and
systemic antibody responses [63–66]. In view of the immunomodulatory properties of
probiotics, one might speculate that the probiotic bacteria may ameliorate symptoms of AD
by modulating the inflammatory reactions driven by Aβ deposition and other risk factors,
including inflammaging, obesity, and traumatic brain injury.
Studies have shown that probiotics could directly mitigate neuroinflammation as observed in
the reductions of circulating pro-inflammatory cytokines and microglia activation. For exam-
ple, chronic inflammation was suppressed after probiotic treatment with L. pentosus var.
plantarum C29 in a D-galactose-induced accelerated aging mouse model for which the activa-
tion of transcription factor nuclear factor-kappa B (NF-κB), the pro-inflammatory cytokine
TNF-α, and M1 macrophages were inhibited [67]. Moreover, administration of B. breve A1
ameliorated Aβ toxicity and prevented cognitive decline in AD model mice through its mod-
ulating effect on the excessive immune response and neuronal inflammation caused by Aβ
injection [54]. Overall, these studies provide a mechanistic insight into the role of probiotics in
modulation of inflammatory responses and amelioration of AD pathology.
5.2. Suppression of oxidative stress
In addition to the established pathology of senile plaques and NFTs, oxidative stress has
emerged as an important factor contributing to the development of AD. Oxidative stress
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represents the mechanism through which Aβ neurotoxic peptides and tau proteins mediate the
pathological processes and cause synaptic impairment, neuroinflammation, neuronal apopto-
sis, and neurotransmitter dyshomeostasis in AD [68] that ultimately correlates with the typical
behavioral symptoms of AD [69]. Oxidative stress is characterized as an imbalance between
the production of ROS and the activities of antioxidant defense system that resulting in
oxidative damage, as observed in AD patients [70]. Mounting evidence suggests that oxidative
damage contributed to the onset and progression of AD wherein low antioxidant enzyme
levels, high oxygen consumption, the presence of excitotoxic amino acids, and high iron content
promote the production of ROS and reactive nitrogen species (RNS) in the brain [71, 72]. In
addition, aberrant accumulation of Aβ can also enhance the generation of ROS through an
N-methyl-D-aspartate (NMDA) receptor-dependent mechanism [73], and that oxidative stress
may augment the production and deposition of Aβ as well as facilitate tau hyperpho-
sphorylation and oligomerization, forming a viscous cycle that promotes the onset and pro-
gression of AD [74]. Therefore, it is tempting to postulate that probiotics with strong
antioxidant potential may prevent and treat AD by counteracting oxidative stress and the
molecular events implicated in the pathogenesis of AD.
A remarkable recent study supports the protective role of probiotics in the brain oxidative
status of AD mice model and demonstrates the molecular mechanisms involved [75]. For
instance, SLAB51 probiotics formulation significantly reduced oxidative damages in AD mice
brain through a mechanism that involves the activation of SIRT1-related pathways [75]. SIRT1
is a deacetylase with a strong neuroprotective and antioxidant potential that regulates the
expression of several antioxidant genes [76, 77]. Reduction of SIRT1 functionality and expres-
sion levels have been reported to contribute to the accumulation of Aβ and tau in the cerebral
cortex of AD patients [78]. It was demonstrated that SLAB51 intervention restored the levels of
SIRT1 by deactivating its nuclear receptor RARβ in AD mice [75], which, in turn, may stimu-
late the nonamyloidogenic pathway of APP processing and diminish Aβ production and
accumulation [79]. Moreover, several studies have also reported that probiotic bacteria
counteracted oxidative damage and improved cognitive impairment in AD rodent models
through its antioxidant properties [56, 80]. Collectively, these findings represent the funda-
mental concept that probiotic ameliorates the symptomatology of AD through its antioxidative
mechanism.
5.3. Modulation of CNS function mediated by bacteria-derived metabolites
Another possible mechanism of action by which probiotics can ameliorate AD is through the
production of metabolites such as short-chain fatty acids (SCFAs). SCFAs, mainly acetate,
butyrate, lactate, and propionate, are the main metabolites of the fermentation of dietary fibers
by the gut microbiota [81]. A study using germ-free mice has revealed a substantial contribu-
tion of the gut microbiota, particularly the microbiota-derived SCFAs, to the regulation of
microglia maturation and functions [82]. In addition, SCFAs have also been shown to play a
role in regulation of several signaling pathways such as inhibition of NF-κB, inhibition of
histone deacetylation (HDAc), and activation of G protein-coupled receptors (GPCRs), and
are well known to have potent anti-inflammatory effects [83–85]. For instance, butyrate has a
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direct stimulation effect on vagal afferents that have been shown in clinical trials to improve
cognitive function of AD patients [86, 87]. Butyrate has also been shown to inhibit HDAc and
improve memory function in a late-stage AD mouse model [88]. In addition, a study using
PC12 cells demonstrated the potential neuroprotective roles of the enteric bacterial metabo-
lites, butyrate and propionate, against AD whereby the expression of Aβ A4 protein precursor
was significantly downregulated by these SCFAs [89]. Meanwhile, acetate supplementation
was shown to be capable of attenuating neuroglia activation and pro-inflammatory cytokine
expression in rat models of neuroinflammation [90].
Recent scientific studies indicate that probiotics modulation of gut microbiota ameliorated the
inflammatory status of AD through the production of SCFAs. For example, in the study of the
probiotic B. breve A1, the cognitive decline of Aβ-induced AD mice was also partially amelio-
rated by its metabolite acetate, implying that the production of SCFAs by the gut microbiota
could be involved in the preventive mechanisms of Aβ-induced neuroinflammation and cog-
nitive impairment [54]. In fact, several SCFAs produced by gut microbiota have been shown to
be capable of potently inhibiting the formation of toxic soluble Aβ aggregates, in vitro [91]. A
growing body of evidence has shown that circulating levels of SCFAs could affect CNS
function [92, 93], suggesting a functional role of SCFAs in the modulation of amyloidosis,
neuroinflammation, and other AD-related conditions in the brain. Moreover, in the 3xTg-AD
mice model (which rapidly develops amyloid plaques and NTFs) treated with the probiotics
SLAB51, the levels of the bacterial metabolites (i.e., propionate and acetate) are elevated [55].
Together with the positive interference of inflammatory cytokines, reduction of Aβ aggregates,
and improvement of cognitive function by SLAB51 treatments, these data contribute to define
the link between bacterial-derived metabolites and AD. Nonetheless, there is still no clear
mechanistic study investigating the underlying mechanisms of SCFAs in the treatment of
neurodegenerative diseases.
In addition, SCFAs were reported to be able to modulate neurotransmitter synthesis and have
effect on the neurotrophic genes including brain-derived neurotrophic factor (BDNF) and
nerve growth factor [92, 94]. Interestingly, a reduction in BDNF signaling was observed in both
the brain and the serum of patients with AD [92], and such decline was reversed by probiotics
intervention as demonstrated in rodent model [52, 95, 96]. These findings suggest that probi-
otic modulation may enhance the production of small ubiquitous microbiota-derived mole-
cules like SCFAs that could act as important molecular signals between the microbiota and
host, thereby improving the molecular events associated with cognitive impairment.
5.4. Amelioration of AD pathogenesis via alteration of gut microbiota composition
Another mechanism to consider is the alteration of gut microbiota composition by probiotics.
Emerging evidence suggests that targeting the gut commensals through probiotics intervention
could mitigate age-associated inflammation and cognitive impairment [52, 97]. It has also been
reported that perturbations of gut microbiota community induced by antibiotic treatment could
ameliorate Aβ deposition and inflammatory responses in an aged APP transgenic mice model of
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AD [98]. Furthermore, many intervention studies in elderly subjects have also demonstrated that
probiotics can augment the growth of the gut commensal, Bifidobacterium, while concomitantly
decreasing the growth of opportunistically pathogenic enterobacteria [99].
While little is currently known regarding the role of the microbiota-gut-brain axis in AD,
several scientific efforts have pointed out that probiotics can modify the gut microbiota for
amelioration of AD-related pathological conditions. For instance, administration of the probi-
otic mixture SLAB51 induced larger shifts in the microbial communities of the 3xTg-AD mice,
along with an increase in the proportions of Bifidobacterium spp. and a reduction in
Campylobacterales population [55], suggesting a possible role of these bacteria in the regulation
of inflammation in AD. This is substantiated by the reduced plasma concentration of pro-
inflammatory cytokines in AD mice treated with SLAB51 [55]. In fact, certain strains of
Bifidobacterium were reported to possess anti-inflammatory properties and could negatively
modulate mRNA levels of pro-inflammatory cytokines produced from LPS-stimulated macro-
phages [100]. In contrary, Campylobacter jejuni and Campylobacter coli have been found to
stimulate pro-inflammatory responses in human peripheral blood mononuclear cells [101]
and chicken models [102]. Moreover, a high prevalence of Campylobacterales infections has been
observed in patients with AD, and the parameters on cognitive function were ameliorated after
Helicobacter pylori eradication [103]. These findings suggest that the alteration of gut microbial
composition by probiotics could positively modulate the AD-related pathological conditions.
Nevertheless, translational study in human subjects is undoubtedly required in order to deter-
mine whether probiotics modulation of the gut microbiota could display efficacy in mitigating
the pathogenesis of AD in humans. Nonetheless, these promising findings suggest that targeting
the microbiota by probiotics intervention could be a useful preventive measure for AD.
6. Conclusions and perspectives
Altogether, the results of the research summarized in this chapter suggest the potential of
probiotics in preventing cognitive impairment in AD. In particular, probiotics intervention
could effectively ameliorate cognitive impairment and symptomatology of AD and can be
considered as an important advance in the field of AD. It is evident that the gut microbiota
composition is altered in AD and the modulation of gut dysbiosis through probiotics could
counteract various benchmarks of AD. Probiotics or its bioactive metabolites can improve gut
microbiota homeostasis and influence the pathological factors involved in the progression of
AD such as inflammatory reaction, oxidative stress, Aβ deposition, and cognitive functions
(Figure 2). Despite still being a speculation, accumulated information from animal and human
research provides fundamental proofs for the modulating effect of probiotics in AD and
underlies the possible mechanisms of action involved. Further studies are definitely needed
to fully elucidate the scope of probiotics for this debilitating disease, as well as to clarify the
underlying mechanisms of probiotics for preventing cognitive impairment in AD.
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Figure 2. Schematic overview of the possible mechanisms of action of probiotics modulation for preventing cognitive
impairment in Alzheimer’s disease (AD). Probiotics or its bioactive metabolites such as SCFAs can improve gut
microbiota homeostasis and positively influence the pathological factors involved in the progression of AD such as
inflammatory reaction and oxidative stress, thereby ameliorating cognitive decline in AD.
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